• In May 2026, Merck & Co., Inc. received a positive CHMP opinion backing KEYTRUDA plus Padcev for certain bladder cancer patients in Europe and reported successful Phase 3 results for sacituzumab tirumotecan in advanced or recurrent endometrial cancer, while also declaring a US$0.85 third-quarter dividend and issuing multi-maturity notes totaling about US$6.00 billion.
• Together, these developments underscore how Merck is pairing an expanding oncology portfolio, centered on KEYTRUDA combinations and new antibody-drug conjugates, with active capital management through dividends and sizable bond financing.
• We’ll now examine how the CHMP backing for KEYTRUDA plus Padcev fits into and potentially reinforces Merck’s existing investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Merck Investment Narrative Recap

To own Merck, you need to believe its expanding oncology and vaccine portfolio can offset future pressures on KEYTRUDA and pricing, while absorbing near term volatility from one off charges and litigation. The CHMP’s backing for KEYTRUDA plus Padcev and the positive sacituzumab tirumotecan data both support the case that Merck’s late stage pipeline is central to the short term catalyst story, while the eventual KEYTRUDA loss of exclusivity remains the core long term risk.

Among the recent announcements, the positive CHMP opinion for KEYTRUDA plus Padcev in cisplatin ineligible muscle invasive bladder cancer is most relevant. It shows how Merck is trying to move KEYTRUDA combinations earlier in treatment and across tumor types, in parallel with new antibody drug conjugates such as sacituzumab tirumotecan. For investors, these oncology readouts are tightly connected to the key catalyst of whether Merck’s pipeline can eventually counterbalance KEYTRUDA’s future exclusivity risk.

Yet some investors may be underestimating the risk that pricing pressure and biosimilars could compound the eventual KEYTRUDA cliff and...

Merck's narrative projects $76.5 billion revenue and $23.7 billion earnings by 2029.

Uncover how Merck's forecasts yield a $129.74 fair value, a 8% upside to its current price.

Exploring Other Perspectives

While the baseline view leans on pipeline breadth, the most pessimistic analysts were only assuming roughly US$71.3 billion of revenue and US$20.4 billion of earnings by 2029, so you should expect that both their concerns about pricing pressure and biosimilars and their longer term forecasts may shift as this new KEYTRUDA and ADC data is fully digested.

Explore 10 other fair value estimates on Merck - why the stock might be worth as much as 91% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Merck research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.